Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive phase II/III trial of topical KX-826 in Chinese adult men with androgenetic alopecia
CTR20243203Phase 3Active
- Sponsor
- Suzhou Kaixi Pharmaceutical
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pyrilutamide in androgenetic alopecia (AGA), sponsored by Suzhou Kaixi Pharmaceutical. Started Oct 2024; status: active.
02
Drugs
pyrilutamide
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on CTR20243203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243203.